Biotech start­up lines up more cash to steer its NASH drug through stormy seas

In Jan­u­ary 2020, Dutch NASH-fo­cused biotech North­Sea Ther­a­peu­tics raised $40 mil­lion in a Se­ries B to progress its lead can­di­date icos­abu­tate, a struc­tural­ly-en­gi­neered fat­ty com­pound …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER